Dyskinesia in Parkinson's disease - major clinical features, aetiology, therapy;Dyskinesien bei morbus Parkinson - Klinik, ätiologie, therapie

Fortschritte der Neurologie Psychiatrie

Volumn 75, Issue 7, 2007, Pages 387-396

  Ellrichmann, Gisa ^a   Russ, H ^a   Muller T ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

Dyskinesias; Parkinson's disease; Therapy of parkinson's disease

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; CABERGOLINE; CLOZAPINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; FIPAMPEZOL; ISTRADEFYLLINE; LEVODOPA; PRAMIPEXOLE; ROPINIROLE; SARIZOTAN; TALAMPANEL; UNCLASSIFIED DRUG;

ATHETOSIS; BRAIN NERVE CELL; CAREGIVER; CHOREA; CLINICAL TRIAL; COGNITION; DRUG ACTIVITY; DRUG EFFECT; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; GLOBUS PALLIDUS; HUMAN; MONOTHERAPY; MOTOR DYSFUNCTION; PARKINSON DISEASE; QUALITY OF LIFE; REVIEW; SOCIOECONOMICS;

ANTIPARKINSON AGENTS; BASAL GANGLIA; DYSKINESIAS; HUMANS; LEVODOPA; NEUROPROTECTIVE AGENTS; NEUROSURGICAL PROCEDURES; PARKINSON DISEASE; QUALITY OF LIFE; RISK FACTORS;

EID: 34547397842     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-944314     Document Type: Review

References (110)

1. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56: S1-S88
2. Reichmann H, Sommer U, Fuchs G et al. Workshop IV: drug treatment guidelines for the long-term management of Parkinson's disease. J Neurol 2000; 247 Suppl 4: IV/40- IV/41
3. Ferreira JJ, Galitzky M, Montastruc JL, Rascol O. Sleep attacks and Parkinson's disease treatment. Lancet 2000; 355: 1333-1334
4. Camp G van, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003; 61: 859-861
5. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005; 62: 1377-1381
6. Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005; 11: 381-386
7. Dewey Jr RB. Management of motor complications in Parkinson's disease. Neurology 2004; 62 (Suppl 4): S3-S7
8. Muenter MD, Sharpless NS, Tyce GM, Darley FL. Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease. Mayo Clin Proc 1977; 52: 163-174
9. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000; 47: S2-S9
10. Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992; 7: 117-124
11. Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 1994; 9: 2-12
12. Adler CH. Relevance of motor complications in Parkinson's disease. Neurology 2002; 58: S51-S56
13. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 2005; 20 Suppl 11: S11-S16
14. Melamed E. Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease. Arch Neurol 1979; 36: 308-310
15. Cubo E, Grades JM, Benabou R, Olanow CW, Raman R, Leurgans S, Goetz CG. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol 2001; 58: 1379-1382
16. Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990; 40: 340-345
17. Rice JE, Antic R, Thompson PD. Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease. Mov Disord 2002; 17: 524-527
18. Rascol O, Fabre N. Dyskinesia: L-dopa-induced and tardive dyskinesia. Clin Neuropharmacol 2001; 24: 313-323
19. Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW. The evolution and origin of motor complications in Parkinson's disease. Neurology 2000; 55: S13-S20
20. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001; 2: 577-588
21. Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 2004; 62: S47-S55
22. Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology 2004; 62: S56-S63
23. Boraud T, Bezard E, Bioulac B, Gross CE. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain 2001; 124: 546-557
24. Widnell K. Pathophysiology of motor fluctuations in Parkinson's disease. Mov Disord 2005; 20 Suppl 11: S17-S22
25. Bonnet AM. Involvement of non-dopaminergic pathways in Parkinson's disease: pathophysiology and therapeutic implications. CNS Drugs 2000; 13: 351-364
26. Nicholson SL, Brotchie JM. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur J Neurol 2002; 9 Suppl 3: 1-6
27. Deogaonkar M, Subramanian T. Pathophysiological basis of drug-induced dyskinesias in Parkinson's disease. Brain Res Brain Res Rev 2005; 50: 156-168
28. Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 2005; 20: 919-931
29. Chase TN, Bibbiani F, Oh JD. Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotox Res 2003; 5: 139-146
30. Calon F, Morissette M, Goulet M, Grondin R, Blanchet PJ, Bedard PJ, Paolo T Di. Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content. Neurochem Int 1999; 35: 81-91
31. Calon F, Paolo T Di. Levodopa response motor complications - GABA receptors and preproenkephalin expression in human brain. Parkinsonism Relat Disord 2002; 8: 449-454
32. Rascol O, Brooks DJ, Korczyn AD, Deyn PP De, Clarke CE, Lang AE for the 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342: 1484-1491
33. Rascol O, Korczyn AD, Deyn PP De, Lang A. Incidence of dyskinesias in a 10-year naturalistic follow-up of patients with early Parkinson's disease (PD) initially receiving ropinirole compared with L-dopa. Mov Disord 2005; 20 (Suppl. 10): S57-S57
34. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005; 62: 905-910
35. Lozano AM, Lang AE, Galvez-Jimenez N et al. Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet 1995; 346: 1383-1387
36. Krack P, Pollak P, Limousin P, Hoffmann D, Xie J, Benazzouz A, Benabid AL. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. Brain 1998; 121 (Pt 3): 451-457
37. Müller T, Hock K. Dyskinesia can first occur at any stage of Parkinson's disease and at any point during L-dopa treatment. Parkinsonism Relat Disord 2005; 11 (Suppl. 2): 131-131
38. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-458
39. The Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508
40. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005; 252 Suppl 4: iv37-iv42
41. Golbe LI. Young-onset Parkinson's disease: a clinical review. Neurology 1991; 41: 168-173
42. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991; 41: 202-205
43. Kumar N, Gerpen JA Van, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord 2005; 20: 342-344
44. Müller T, Russ H, Haeger DA. Dyskinesia occurs in 34% of Parkinson's disease patients receiving dopaminergic treatment: findings from a recent retrospective international survey. Mov Disord 2005; 20 (Suppl. 10): S17-S17
45. Goetz CG. Rating scales for dyskinesias in Parkinson's disease. Mov Disord 1999; 14: 48-53
46. Fahn S, Elton RL UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, eds. Recent developments in Parkinson's disease. Florham Park: MacMillan Healthcare Information, 1987: 153-163
47. Abnormal Involuntary Movement Scale. ECDEU Assessment Manual for Psychopharmacology. Washington: US Government Printing Office, 1976: 534-537
48. Goetz CG, Stebbins GT, Shale HM et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord 1994; 9: 390-394
49. Hauser RA, Friedlander J, Zesiewicz TA et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000; 23: 75-81
50. Parkinson Study Group. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Arch Neurol 2001; 58: 1660-1668
51. Hauser RA, Deckers F, Lehert P. Parkinson's disease home diary: further validation and implications for clinical trials. Mov Disord 2004; 19: 1409-1413
52. Hauser RA, Russ H, Hall J, Haeger DA, Muller T. Patient evaluation of a new diary for assessing duration and severity of dyskinesia in patients with Parkinson's disease. Parkinsonism Relat Disord 2005; 11: 157-157
53. Goetz CG, Stebbins GT, Blasucci LM, Grobman MS. Efficacy of a patient-training videotape on motor fluctuations for on-off diaries in Parkinson's disease. Mov Disord 1997; 12: 1039-1041
54. Damiano AM, McGrath MM, Willian MK et al. Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life. Qual Life Res 2000; 9: 87-100
55. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005; 20: 224-230
56. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000; 123: 2297-2305
57. Schrag A, Selai C, Jahanshahi M, Quinn NP. The EQ-5D - a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 69: 67-73
58. Marras C, Lang A, Krahn M, Tomlinson G, Naglie G. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. Mov Disord 2004; 19: 22-28
59. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 1995; 4: 241-248
60. Dodel RC, Singer M, Kohn-Volland R et al. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective anaylsis. Pharmacoeconomics 1998; 14: 299-312
61. LePen C, Wait S, Moutard-Martin F, Dujardin M, Ziegler M. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999; 16: 59-69
62. Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001; 19: 1013-1038
63. Maurel F, Lilliu H, Pen C Le. [Social and economic cost of L-dopa-induced dyskinesias in patients with Parkinson's disease]. Rev Neurol (Paris) 2001; 157: 507-514
64. Fahn S. Is levodopa toxic? Neurology 1996; 47: S184-S195
65. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-1661
66. Whone AL, Watts RL Stoessl AJ et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54: 93-101
67. Goetz CG, Poewe W, Rascoi O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005; 20: 523-539
68. Rinne UK, Bracco F, Chouza C et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998; 55 Suppl 1: 23-30
69. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA 2000; 284: 1931-1938
70. Smith LA, Jackson MJ, Al Barghouthy G et al. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 2005; 20: 306-314
71. Heindl M, Scheller D, Lebsanft H, Schmidt WJ. Continuous versus discontinuous administration of rotigotine in a rat model of dyskinesia. Parkinsonism Relat Disord 2005; 11 (Suppl. 2): 103-103
72. Blanchet PJ, Colon F, Martel JC et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 1995; 272: 854-859
73. Marin C, Aguilar E, Obeso JA. Entacapone, a COMT inhibitor, attenates the severity of levodopa-induced dyskinesias in hemiparkinsonian rats. Neurology 2004; 19: S257-S257
74. Scheller D, Kehr J. Evidence for continuous dopamine receptor stimulation by rotigotine in freely moving rats using a continuous delivery system. Parkinsonism Relat Disord 2005; 11 (Suppl. 2): 103-103
75. Watts RL, Wendt J, Nausieda PA, Poole K, Sommerville KW, Bovbjerg VE. Efficacy, safety, and tolerability of the rotigotine transdermal patch in patients with early-stage, idiopathic Parkinson's disease. A multicenter, multinational, randomized, double-blind, placebo-controlled trial. Mov Disord 2004; 19 (Suppl. 9): 258
76. Cristina S, Zangaglia R, Mancini F, Martignoni E, Nappi G, Pacchetti C. High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias. Clin Neuropharmacol 2003; 26: 146-150
77. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 573-576
78. Verhagen ML, Dotto P Del, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998; 50: 1323-1326
79. Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev, 2003 CD003467,
80. Paci C, Thomas A, Onofrj M. Amantadine for dyskinesia in patients affected by severe Parkinson's disease. Neurol Sci 2001; 22: 75-76
81. Thomas A, Iacono D, Luciano AL, Armellino K, Iorio A Di, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 141-143
82. Verhagen Metman L, Dotto P Del, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999; 56: 1383-1386
83. Durif F, Debilly B, Galitzky M et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004; 62: 381-388
84. Lang AE, Lozano AM, Montgomery E, Duff J, Tasker R, Hutchinson W. Posteroventral medial pallidotomy in advanced Parkinson's disease. N Engl J Med 1997; 337: 1036-1042
85. Vitek JL, Bakay RA, Freeman A et al. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. Ann Neurol 2003; 53: 558-569
86. The Deep-Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001; 345: 956-963
87. Vitek JL. Deep brain stimulation for Parkinson's disease. A critical reevaluation of STN versus GPi DBS. Stereotact Funct Neurosurg 2002; 78: 119-131
88. Krack P, Batir A, Blercom N Van et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003; 349: 1925-1934
89. Bartoszyk CD, Amsterdam C Van, Greiner HE et al. Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. J Neural Transm 2004; 111: 113-126
90. Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001; 57: 1829-1834
91. Olanow CW, Damier P, Goetz CG et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 2004; 27: 58-62
92. Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin Investig Drugs 2005; 14: 729-738
93. Bara-Jimenez W, Sherzai A, Dimitrova T et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003; 61: 293-296
94. Hauser RA, Hubble JP, Truong DD. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003; 61: 297-303
95. LeWitt PA and the 6002-US-005/6002-US-006 Clinical Investigator Group. 'OFF' time reduction from adjunctice use of istradefylline (KW-6002) in levodopa-treated patients with advanced Parkinson's disease. Mov Disord 2004; 19 (Suppl. 9): 222
96. Savola JM, Hill M, Engstrom M et al. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 2003; 18: 872-883
97. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 2000; 54: 1589-1595
98. Johnston TH, Brotchie JM. Drugs in development for Parkinson's disease. Curr Opin Investig Drugs 2004; 5: 720-726
99. Hill MP, Ravenscroft P, Bezard E et al. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. J Pharmacol Exp Ther 2004; 310: 386-394
100. Bezard E, Hill MP, Crossman AR et al. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Eur J Pharmacol 2004; 485: 159-164
101. Zesiewicz TA, Sullivan KL, Maldonado JL, Tatum WO, Hauser RA. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2005; 20: 1205-1209
102. Meco G, Fabrizio E, Epifanio A, Raimondo G Di, Vanacore N, Morgante L Levetiracetam in l-dopa induced dyskinesia. Clinical Neuropharmacology 2005; 28: 102-103
103. Michel A, Ravenscroft P et al. Seletracetam (UCB 44 212) reduces L-dopa dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. Mov Disord 2005; 20 (Suppl. 10): S57-S57
104. Bezard E, Ferry S, Mach U, Stark H, Leriche L, Boraud T, Gross C, Sokoloff P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003; 9: 762-767
105. Hsu A, Togasaki DM, Bezard E, Sokoloff P, Langston JW, Monte DA Di, Quik M. Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. J Pharmacol Exp Ther 2004; 311: 770-777
106. Weiner DM, Vanover KE, Hacksell U, Brann MR, Davis RE. The tolerability of ACP-103, a 5-HT2a receptor inverse agonist in Parkinson's disease patients. Mov Disord 2005; 20 (Suppl. 10): S241-S241
107. Olanow CW. Surgical therapy for Parkinson's disease. Eur J Neurol 2002; 9 Suppl 3: 31-39
108. Watts RL, Raiser CD, Stover NP et al. Stereotaxic intrastriatal implantation of human retinal pigment epithelial (hRPE) cells attached to gelatin microcarriers: a potential new cell therapy for Parkinson's disease. J Neural Transm Suppl 2003; (65): 215-227
109. Bakay RA, Raiser CD, Stover NP et al. Implantation of spheramine in advanced Parkinson's disease (PD). Front Biosci 2004; 9: 592-602
110. Doudet DJ, Cornfeldt ML, Honey CR et al. PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of Parkinson's disease. Exp Neurol 2004; 189: 361-368